Fundraising FoxModi Ventures — 2024 Investments
3 investments dated 2024 · listed companies and verified rows first · show all
Glyphic Biotechnologies develops ProSE™, a high-throughput de novo protein sequencing technology for analyzing proteomes with single-molecule sensitivity.
BiotechDeep TechBerkeley, US
Daniel Estandian(Founder)inEd Boyden(Founder)Josh Yang(Founder)inJoshua Yang(Founder)
BoardCraig Asher(Director)inJimmy Yun(Director)in
Co-investorsArtis VenturesBlack FlagCivilization Ventures Management, LlcFoundersX VenturesGaingelsHarpoon Ventures+10 more
__Twitter.png)
Outpace Bio develops engineered protein technologies and cell therapies to treat solid tumors, focusing on protein design and T cell engineering to improve cancer treatment efficacy and safety.
BiotechDeep TechMedical DevicesSeattle, US
Marc Lajoie(Founder)inScott Boyken(Founder)inStanley Riddell(Co-Founder and Scientific Advisor)Aaron Foster(Executive Officer)inCharity Scripture(Executive Officer)inEric Soller(Executive Officer)in
Co-investorsArtis VenturesRA CapitalAbstract VenturesATEL VenturesAtinum Investment Co. Ltd.Civilization Ventures Management, Llc+9 more
Tiny Health offers at-home gut and vaginal microbiome test kits with age-specific, evidence-based reports that recommend diet, supplement, and lifestyle changes.
Digital HealthHealthtechWellness & Fitness
Cheryl Sew Hoy(Founder)in
Co-investorsAlumni VenturesB Capital GroupB4 CapitalCartan CapitalNext Coast VenturesNorth South Ventures+11 more
.jpeg){kind=logo}
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.